TCS shines on the bourses

TCS is currently trading at Rs. 1511.35, up by 11.80 points or 0.79% from its previous closing of Rs. 1499.55 on the BSE.

The scrip opened at Rs. 1495.00 and has touched a high and low of Rs. 1512.00 and Rs. 1490.25 respectively. So far 46,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1520.00 on 28-Feb-2013 and a 52 week low of Rs. 1046.55 on 23-Apr-2012.

Last one week high and low of the scrip stood at Rs. 1520.00 and Rs. 1452.00 respectively. The current market cap of the company is Rs. 2, 95,804 crore.

The promoters holding in the company stood at 73.96% while Institutions and Non-Institutions held 21.41% and 4.63% respectively.

Tata Consultancy Services (TCS), a leading IT services, consulting and business solutions organization has been chosen as a Leader in Life Science Drug Safety Services (DSS) by the prominent global market intelligence firm IDC. The company got leadership position due to its large life science customer base, broad industry-centric services portfolio, competitive pricing, and strong commitment to growth ensure that the company will continue to be a leading service provider to the industry over both the near and long term.

IDC MarketScape reports are designed to identify factors conducive to success in a particular market, both long term and short term, and then assess vendors participating in the market against these factors. The criteria for each IDC MarketScape report is developed by IDC analysts and can include discussions, surveys and interviews. For this report, the key criteria for defining excellence included: breadth of service offerings, diversity of resources and infrastructure-supporting services delivery, project experience in the Life Sciences DSS outsourcing market, customer service strategy and customer satisfaction, pricing model, go-to-market capabilities and commitment to growth and innovation in the R&D DSS space.

The company’s drug safety services help customers enhance efficiency, reduce costs significantly and ensure regulatory compliance. TCS’ customers benefit from the company’s domain knowledge, global reach, quality systems approach, multi-disciplinary safety expertise and adherence to reporting timelines of the EMEA, FDA, MHRA and other industry authorities.